WP
RVPH

Woodline Partners’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Woodline Partners’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,240
Closed -$986K – 986
2024
Q3 		$986K Sell
34,240
-45,399
-57% -$1.01M 0.01% 509
2024
Q2 		$2.04M Buy
79,639
+26,889
+51% +$1.22M 0.02% 412
2024
Q1 		$3.99M Buy
52,750
+46,730
+776% +$3.7M 0.04% 383
2023
Q4 		$620K Buy
+6,020
New +$540K 0.01% 420

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners's RVPH Position: Q4 2024 in Review

Woodline Partners sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q4 2024, closing a stake of 34,240 shares — an estimated $986K sold.

Woodline Partners first reported a position in RVPH in Q4 2023 and held it in 4 quarters. The position peaked at $3.99M in Q1 2024. 42 funds tracked by Wall St. Rank hold RVPH as of Q4 2024.

  • Woodline Partners reported no remaining REVIVA PHARMA HLDGS INC position as of Q4 2024 after selling out during the quarter.
  • Woodline Partners sold 34,240 REVIVA PHARMA HLDGS INC shares in Q4 2024, an estimated $986K.
  • Woodline Partners first reported a position in REVIVA PHARMA HLDGS INC in Q4 2023 and held it in 4 quarters.
  • Woodline Partners's REVIVA PHARMA HLDGS INC position peaked at $3.99M in Q1 2024.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.